TY - JOUR
T1 - Characterization of translational frame exception patients in duchenne/becker muscular dystrophy
AU - Winnard, Alissa V.
AU - Klein, Christopher J.
AU - Coovert, Daniel D.
AU - Prior, Thomas
AU - Papp, Audrey
AU - Snyder, Pamela
AU - Bulman, Dennis E.
AU - Ray, Peter N.
AU - Mcandrew, Patricia
AU - King, Wendy
AU - Moxley, Richard T.
AU - Mendell, Jerry R.
AU - Burghes, Arthur H.M.
N1 - Funding Information:
We would like to thank K.Burrows and L.Paul for assistance with immunocytochemistry, N.Hodges for typing the manuscript and S.Coulson for critically reading the manuscript. This work was supported by NIH Grant R29 AR40015-01 and the Muscular Dystrophy Association. D.E.B. is an awardee of the Arthur Minden Predoctoral Award through the Muscular Dystrophy Association of Canada, D.D.C. is supported by a March of Dimes Predoctoral Award and A.V.W. is supported by a Proctor and Gamble Fellowship.
PY - 1993/6
Y1 - 1993/6
N2 - The clinical progression of Duchenne muscular dystrophy (DMD) patients with deletions can be predicted in 93% of cases by whether the deletion maintains or disrupts the translational reading frame (frameshift hypothesis). We have identified and studied a number of patients who have deletions that do not conform to the translational frame hypothesis. The most common exception to the frameshift hypothesis is the deletion of exons 3 to 7 which disrupts the translational reading frame. We identified a Becker muscular dystrophy (BMD) patient, an intermediate, and a DMD patient with this deletion. In all three cases, dystrophin was detected and localized to the membrane. One DMD patient with an inframe deletion of exons 4-18 produced no dystrophin. One patient with a mild intermediate phenotype and a deletion of exon 45, which shifts the reading frame, produced no dystrophin. Two patients with large inframe deletions had discordant phenotypes (exons 3-41, DMD; exons 13-48, BMD), but both produced dystrophin that localized to the sarcolemma. The DMD patient, 113, indicates that dystrophin with an intact carboxy terminus can be produced in Duchenne patients at levels equivalent to some Beckers. The dystrophin analysis from these patients, together with patients reported in the literature, indicate that more than one domain can localize dystrophin to the sarcolemma. Lastely, the data shows that although most patients show correlation of clinical severity to molecular data, there are rare patients which do not conform.
AB - The clinical progression of Duchenne muscular dystrophy (DMD) patients with deletions can be predicted in 93% of cases by whether the deletion maintains or disrupts the translational reading frame (frameshift hypothesis). We have identified and studied a number of patients who have deletions that do not conform to the translational frame hypothesis. The most common exception to the frameshift hypothesis is the deletion of exons 3 to 7 which disrupts the translational reading frame. We identified a Becker muscular dystrophy (BMD) patient, an intermediate, and a DMD patient with this deletion. In all three cases, dystrophin was detected and localized to the membrane. One DMD patient with an inframe deletion of exons 4-18 produced no dystrophin. One patient with a mild intermediate phenotype and a deletion of exon 45, which shifts the reading frame, produced no dystrophin. Two patients with large inframe deletions had discordant phenotypes (exons 3-41, DMD; exons 13-48, BMD), but both produced dystrophin that localized to the sarcolemma. The DMD patient, 113, indicates that dystrophin with an intact carboxy terminus can be produced in Duchenne patients at levels equivalent to some Beckers. The dystrophin analysis from these patients, together with patients reported in the literature, indicate that more than one domain can localize dystrophin to the sarcolemma. Lastely, the data shows that although most patients show correlation of clinical severity to molecular data, there are rare patients which do not conform.
UR - http://www.scopus.com/inward/record.url?scp=0027207248&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027207248&partnerID=8YFLogxK
U2 - 10.1093/hmg/2.6.737
DO - 10.1093/hmg/2.6.737
M3 - Article
C2 - 8353493
AN - SCOPUS:0027207248
SN - 0964-6906
VL - 2
SP - 737
EP - 744
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 6
ER -